Category

Cohort News

Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery

Avelas Biosciences, Inc., pioneering the field of intraoperative fluorescent cancer imaging, today announced that the company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for pegloprastide (AVB-620) for the intraoperative detection and visualization of positive margins during breast cancer surgery.
Read More →

GT Medical Technologies Announces $16 Million Financing to Expand Availability of Targeted Therapy for Patients with Recurrent Brain Tumors

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTech Venture Partners and BlueStone Venture Partners.
Read More →